Gordon Cook

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1051363/publications.pdf

Version: 2024-02-01

137 papers	6,793 citations	87843 38 h-index	66879 78 g-index
142 all docs	142 docs citations	142 times ranked	6611 citing authors

#	Article	IF	Citations
1	First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC) Tj ETQq1 1 0.784314 rgBT /Over	6.3	505
2	Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood, 2020, 136, 2881-2892.	0.6	479
3	Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study. Journal of Clinical Oncology, 2013, 31, 2540-2547.	0.8	372
4	The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood, 2012, 119, 7-15.	0.6	315
5	APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nature Communications, 2015, 6, 6997.	5.8	261
6	Guidelines for the diagnosis and management of multiple myeloma 2011. British Journal of Haematology, 2011, 154, 32-75.	1.2	252
7	Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2019, 20, 57-73.	5.1	245
8	Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX. Haematologica, 2018, 103, 2088-2096.	1.7	187
9	Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. Blood, 2011, 118, 1231-1238.	0.6	179
10	Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction. Blood, 2015, 125, 1932-1935.	0.6	163
11	Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. Leukemia, 2020, 34, 1875-1884.	3.3	163
12	Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial. Lancet Oncology, The, 2011, 12, 743-752.	5.1	151
13	American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, BloodÂand Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2015, 21, 2039-2051.	2.0	146
14	Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set. Blood, 2020, 136, 3033-3040.	0.6	146
15	Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results. Haematologica, 2012, 97, 442-450.	1.7	144
16	Long-term Follow-up of MRC Myeloma IX Trial: Survival Outcomes with Bisphosphonate and Thalidomide Treatment. Clinical Cancer Research, 2013, 19, 6030-6038.	3.2	143
17	High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI) Tj ETQq1 1 0.784314 rgBT /Overl 15, 874-885.	5.1	139
18	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncology, The, 2021, 22, e105-e118.	5.1	136

#	Article	IF	Citations
19	CD4⁺CD25⁺FoxP3⁺ regulatory T cells are increased whilst CD3⁺CD4^{â^'}CD8^{â^'}Î±Î²TCR⁺ Double Negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden. British Journal of Haematology, 2009, 144, 686-695.	1.2	131
20	The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. Lancet Haematology,the, 2016, 3, e340-e351.	2.2	120
21	Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project. Journal of Clinical Oncology, 2022, 40, 3406-3418.	0.8	115
22	Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). Leukemia, 2020, 34, 2000-2011.	3.3	109
23	Transforming growth factor Î² from multiple myeloma cells inhibits proliferation and IL-2 responsiveness in T lymphocytes. Journal of Leukocyte Biology, 1999, 66, 981-988.	1.5	92
24	Realâ€world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVIDâ€19 disease) in patients with multiple myeloma receiving systemic antiâ€cancer therapy. British Journal of Haematology, 2020, 190, e83-e86.	1.2	92
25	Suppression of IL-2-Induced T Cell Proliferation and Phosphorylation of STAT3 and STAT5 by Tumor-Derived TGFÎ² Is Reversed by IL-15. Journal of Immunology, 2001, 167, 553-561.	0.4	72
26	A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study. Lancet Haematology,the, 2019, 6, e154-e166.	2.2	71
27	International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. Leukemia, 2021, 35, 18-30.	3.3	69
28	Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. Leukemia, 2018, 32, 1542-1560.	3.3	68
29	Tumour Cell Generation of Inducible Regulatory T-Cells in Multiple Myeloma Is Contact-Dependent and Antigen-Presenting Cell-Independent. PLoS ONE, 2012, 7, e35981.	1.1	68
30	Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients. Haematologica, 2019, 104, 1440-1450.	1.7	67
31	Factors Influencing the Outcome of a Second Autologous Stem Cell Transplant (ASCT) in Relapsed Multiple Myeloma: A Study from the British Society ofÂBlood and Marrow Transplantation Registry. Biology of Blood and Marrow Transplantation, 2011, 17, 1638-1645.	2.0	59
32	Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials. Blood, 2020, 136, 1091-1104.	0.6	58
33	The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial. Leukemia, 2020, 34, 604-612.	3.3	56
34	High-dose therapy and autologous stem cell transplantation in patients with POEMS syndrome: a retrospective study of the Plasma Cell Disorder sub-committee of the Chronic Malignancy Working Party of the European Society for Blood & Marrow Transplantation. Haematologica, 2017, 102, 160-167.	1.7	49
35	COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. Lancet Haematology,the, 2021, 8, e934-e946.	2.2	46
36	Defining the vulnerable patient with myelomaâ€"a frailty position paper of the European Myeloma Network. Leukemia, 2020, 34, 2285-2294.	3.3	45

#	Article	IF	Citations
37	Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients. Haematologica, 2021, 106, 2754-2758.	1.7	45
38	Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. HemaSphere, 2021, 5, e528.	1.2	45
39	Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Haematology,the, 2019, 6, e616-e629.	2.2	42
40	Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen. Haematologica, 2016, 101, e69-e71.	1.7	41
41	Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies. Haematologica, 2020, 105, 468-477.	1.7	41
42	Multiple myeloma: routes to diagnosis, clinical characteristics and survival â€“ findings from a ‹scp›UK‹/scp› populationâ€based study. British Journal of Haematology, 2017, 177, 67-71.	1.2	39
43	Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA. Leukemia, 2022, 36, 1066-1077.	3.3	39
44	Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma. Drugs, 2016, 76, 853-867.	4.9	34
45	Regulating the regulators in cancer-immunosuppression in multiple myeloma (MM). Blood Reviews, 2013, 27, 155-164.	2.8	31
46	A molecular diagnostic approach able to detect the recurrent genetic prognostic factors typical of presenting myeloma. Genes Chromosomes and Cancer, 2015, 54, 91-98.	1.5	31
47	Subclonal TP53 copy number is associated with prognosis in multiple myeloma. Blood, 2018, 132, 2465-2469.	0.6	29
48	Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphoma. British Journal of Haematology, 2019, 184, 999-1005.	1.2	29
49	Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk. Journal of Clinical Oncology, 2022, 40, 2889-2900.	0.8	29
50	A question of class: Treatment options for patients with relapsed and/or refractory multiple myeloma. Critical Reviews in Oncology/Hematology, 2018, 121, 74-89.	2.0	28
51	Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21. , 2019, 7, 164.		27
52	Myeloma: Patient accounts of their pathways to diagnosis. PLoS ONE, 2018, 13, e0194788.	1.1	26
53	Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients. Leukemia, 2020, 34, 3091-3096.	3.3	26
54	Optimizing the management of patients with spinal myeloma disease. British Journal of Haematology, 2015, 171, 332-343.	1.2	25

#	Article	IF	Citations
55	The use of single armed observational data to closing the gap in otherwise disconnected evidence networks: a network meta-analysis in multiple myeloma. BMC Medical Research Methodology, 2018, 18, 66.	1.4	24
56	Patient-Reported Outcome Results From the Open-Label, Randomized Phase III Myeloma X Trial Evaluating Salvage Autologous Stem-Cell Transplantation in Relapsed Multiple Myeloma. Journal of Clinical Oncology, 2019, 37, 1617-1628.	0.8	24
57	INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma. Future Oncology, 2019, 15, 1411-1428.	1.1	23
58	Copy number evolution and its relationship with patient outcomeâ€"an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial. Leukemia, 2021, 35, 2043-2053.	3.3	23
59	Key findings from the UKCCMP cohort of 877 patients with haematological malignancy and COVIDâ€19: disease control as an important factor relative to recent chemotherapy or antiâ€CD20 therapy. British Journal of Haematology, 2022, 196, 892-901.	1.2	23
60	Efficacy of Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients with 1 to 3 Prior Lines of Therapy: Updated Analysis of Pollux. Blood, 2016, 128, 1151-1151.	0.6	22
61	Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus lowâ€dose dexamethasone: A pooled analysis. European Journal of Haematology, 2017, 99, 199-206.	1.1	21
62	Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US. Annals of Hematology, 2021, 100, 2325-2337.	0.8	21
63	Neutral tumor evolution in myeloma is associated with poor prognosis. Blood, 2017, 130, 1639-1643.	0.6	20
64	Outcomes Following Salvage Autologous Stem Cell Transplant (ASCT2) Vs Low Dose Alkylating Consolidation Therapy Following Bortezomib-Containing Re-Induction for Relapsed Multiple Myeloma (MM) May be Dependent on Age and Symptomatic Status Initiation of Re-Induction: Results from the Myeloma X (Intensive) Trial. Blood, 2015, 126, 1981-1981.	0.6	20
65	Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial. British Journal of Haematology, 2015, 170, 336-348.	1.2	19
66	Downregulation of myeloma-induced ICOS-L and regulatory T cell generation by lenalidomide and dexamethasone therapy. Cellular Immunology, 2015, 297, 1-9.	1.4	19
67	Time to redefine Myeloma. British Journal of Haematology, 2015, 171, 1-10.	1.2	18
68	Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network. Haematologica, 2019, 104, 2358-2360.	1.7	18
69	Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial. PLoS Medicine, 2021, 18, e1003454.	3.9	18
70	Augmenting Autologous Stem Cell Transplantation to Improve Outcomes in Myeloma. Biology of Blood and Marrow Transplantation, 2016, 22, 1926-1937.	2.0	16
71	Lenalidomide before and after ASCT for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial. Haematologica, 2020, 106, haematol.2020.247130.	1.7	16
72	Autologous stem cell transplantation is safe and effective for fit older myeloma patients: exploratory results from the Myeloma XI trial. Haematologica, 2020, Online ahead of print, 0-0.	1.7	16

#	Article	IF	Citations
73	Immune response to <scp>COVID</scp>â€19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent Tâ€cell response. British Journal of Haematology, 2022, 197, 293-301.	1.2	16
74	RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature. Blood, 2018, 132, 2154-2165.	0.6	14
75	The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (longâ€term followâ€up results from <scp>BSBMT</scp>/<scp>UKMF</scp> Myeloma X) Tj ETQq1 1 0.784314 rgBT 450-467.	1.2	14
76	Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, openâ€label, randomised, Phase III trial. British Journal of Haematology, 2021, 192, 853-868.	1.2	14
77	Effect of combined dexamethasone/lenalidomide therapy on NK cellâ€“receptor levels in myeloma patients. Blood, 2011, 118, 6465-6466.	0.6	13
78	Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX. Blood Cancer Journal, 2020, 10, 111.	2.8	13
79	Healthâ€related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial. British Journal of Haematology, 2021, 194, 132-139.	1.2	13
80	COVID symptoms, testing, shielding impact on patientâ€reported outcomes and early vaccine responses in individuals with multiple myeloma. British Journal of Haematology, 2022, 196, 95-98.	1.2	13
81	Thalidomide Maintenance Significantly Improves Progression-Free Survival (PFS) and Overall Survival (OS) of Myeloma Patients When Effective Relapse Treatments Are Used: MRC Myeloma IX Results. Blood, 2010, 116, 623-623.	0.6	13
82	Minimal Residual Disease in the Maintenance Setting in Myeloma: Prognostic Significance and Impact of Lenalidomide. Blood, 2017, 130, 904-904.	0.6	12
83	An enhanced genetic model of relapsed IGH-translocated multiple myeloma evolutionary dynamics. Blood Cancer Journal, 2020, 10, 101.	2.8	11
84	ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma. Transplantation and Cellular Therapy, 2022, 28, 284-293.	0.6	11
85	Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial. BMJ Open, 2022, 12, e056147.	0.8	11
86	Three-Year Follow up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM). Blood, 2018, 132, 1996-1996.	0.6	10
87	Impact of Minimal Residual Disease in Transplant Ineligible Myeloma Patients: Results from the UK NCRI Myeloma XI Trial. Blood, 2016, 128, 245-245.	0.6	10
88	Reâ€transplantation after bortezomibâ€based therapy. British Journal of Haematology, 2011, 153, 666-668.	1.2	8
89	Stem Cell Harvesting after Bortezomib-Based Reinduction for Myeloma Relapsing after Autologous Transplantation: Results from the British Society of Blood and Marrow Transplantation/United Kingdom Myeloma Forum Myeloma X (Intensive) Trial. Biology of Blood and Marrow Transplantation, 2016, 22, 1009-1016.	2.0	8
90	The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial. Trials, 2018, 19, 169.	0.7	8

#	Article	IF	Citations
91	Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study. British Journal of Haematology, 2021, 193, 750-760.	1.2	8
92	Ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory myeloma: MUKeight phase II randomised controlled trial results. Blood Cancer Journal, 2022, 12, 52.	2.8	8
93	Cyclophosphamide Exerts Significant Immunomodulatory Function in Myeloma Patients Treated with Pomalidomide and Dexamethasone. Blood, 2018, 132, 4482-4482.	0.6	6
94	A Quadruplet Regimen Comprising Carfilzomib, Cyclophosphamide, Lenalidomide, Dexamethasone (KCRD) Vs an Immunomodulatory Agent Containing Triplet (CTD/CRD) Induction Therapy Prior to Autologous Stem Cell Transplant: Results of the Myeloma XI Study. Blood, 2018, 132, 302-302.	0.6	6
95	Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR. Leukemia, 2021, 35, 1732-1744.	3.3	5
96	Progression Free Survival below 12 Months Following Stem Cell Transplant Is a Hallmark of High-Risk Myeloma Which Is Associated with Inferior Overall Survival â€" Data from the Ukmrc Myeloma XI Trial. Blood, 2018, 132, 122-122.	0.6	5
97	Treatment Patterns & Survival In Multiple Myeloma Patients Sequentially Exposed To Thalidomide, Bortezomib & Lenalidomide In a UK Single Centre. Blood, 2013, 122, 5380-5380.	0.6	5
98	Patient perceptions of second transplants in myeloma: impact on recruitment in the British Society of Blood and Marrow Transplantation/UK Myeloma Forum Myeloma X Relapse (Intensive) Trial. British Journal of Haematology, 2013, 163, 541-543.	1.2	4
99	Daratumumab Monotherapy for Relapsed or Refractory Multiple Myeloma: Results of an Early Access Treatment Protocol in Europe and Russia. Oncology and Therapy, 2021, 9, 139-151.	1.0	4
100	Transplant Status Does Not Impact the Selection of Induction Regimens for Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) in the Insight MM Prospective, Observational Study. Blood, 2018, 132, 3289-3289.	0.6	4
101	The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitor. Trials, 2020, 21, 826.	0.7	3
102	Using depth of response to stratify patients to front line Autologous Stem Cell Transplant: results of the phase II PADIMAC Myeloma Trial. British Journal of Haematology, 2021, 193, e19-e22.	1.2	3
103	Optimising Bone Disease In Myeloma; Zoledronic Acid Plus Thalidomide Combinations Improves Survival and Bone Endpoints: Results of the MRC Myeloma IX Trial. Blood, 2010, 116, 311-311.	0.6	3
104	Safety and efficacy of daratumumab-based regimens in elderly (â‰¥75 y) patients (Pts) with relapsed or refractory multiple myeloma (RRMM): Subgroup analysis of POLLUX and CASTOR.. Journal of Clinical Oncology, 2017, 35, 8033-8033.	0.8	3
105	Lenalidomide Combined With Cyclophosphamide and Dexamethasone Is Effective and Well Tolerated Induction Treatment For Newly Diagnosed Myeloma Patients Of All Ages. Blood, 2013, 122, 540-540.	0.6	3
106	Evolution or revolution in multiple myeloma therapy and the role of the UK. British Journal of Haematology, 2020, 191, 542-551.	1.2	3
107	Molecular Treatment Stratification for Newly Diagnosed High-Risk Myeloma, Including Plasma Cell Leukemia - Feasibility Results of the Ukmra Optimum: MUK9 Trial (NCT03188172). Blood, 2019, 134, 3162-3162.	0.6	2
108	MRC Myeloma IX, 6 Year Median Follow-up (FU) Highlights the Importance of Long-Term FU in Myeloma Clinical Trials and Differential Effects of Thalidomide in High- and Low-Risk Disease. Blood, 2011, 118, 993-993.	0.6	2

#	Article	IF	Citations
109	Bortezomib (Velcade), Thalidomide, Dexamethasone and Panobinostat (VTD-P) Is a Safe, Well Tolerated and Efficacious Regimen for Patients with Relapsed Multiple Myeloma: Preliminary Results of the Muk-Six Trial. Blood, 2015, 126, 1826-1826.	0.6	2
110	National, Retrospective, Multi-Centre Comparison of Alemtuzumab- Versus ATG-Based Conditioning Regimens in Hematopoietic Stem Cell Transplantation for Aplastic Anemia: A Study From the British Society for Blood and Marrow Transplantation (BSBMT) (CTCR 09-03). Blood, 2011, 118, 52-52.	0.6	2
111	Maximizing Pre-Transplant Response Is Associated with Improved Outcome for Myeloma Patients: Exploratory Analysis of the Myeloma XI Trial. Blood, 2018, 132, 3280-3280.	0.6	2
112	The â€œNext Big Thingâ€•in Treatment for Relapsed or Refractory Multiple Myeloma May Be Held Back by Designâ€”Between the Lines. JAMA Oncology, 2016, 2, 1405.	3.4	1
113	How to Simplify the Evaluation of Newly Introduced Chemotherapeutic Interventions in Myeloma. Clinical Hematology International, 2021, 3, 27.	0.7	1
114	The Roel of High Dose Chemotherapy and Autologous Stem Cell Transplantation (ASCT) In PATIENTS with POEMS SYNDROME: A Retrospective study of the MM Subcommittee of the Chronic Leukemia Working Party of the EBMT,. Blood, 2011, 118, 4115-4115.	0.6	1
115	Identifying An Optimally Effective But Tolerable Dose Of Bendamustine In Combination With Thalidomide and Dexamethasone In Patients With Relapsed Or Refractory Multiple Myeloma. Blood, 2013, 122, 286-286.	0.6	1
116	Subcutaneous PAD As Induction Therapy for Patients with Newly Diagnosed Myeloma: A Phase 2 Trial Assessing the Impact of Minimal Residual Disease (MRD) in Patients with Deferred Autologous Stem Cell Transplantation (PADIMAC). Blood, 2014, 124, 4745-4745.	0.6	1
117	Immune Biomarkers Identify Sustained Quantitative and Functional Immune Reconstitution in the Setting of Adjunctive Lenalidomide Following T-Depleted RIC-Allo SCT for Multiple Myeloma. Blood, 2016, 128, 4585-4585.	0.6	1
118	Efficacy and side-effect profile of long-term bisphosphonate therapy in patients (pts) with multiple myeloma (MM): MRC myeloma IX study results.. Journal of Clinical Oncology, 2012, 30, 8015-8015.	0.8	1
119	A New Multinational Observational Study In Multiple Myeloma: Initial Report Of The PREAMBLE Study. Blood, 2013, 122, 1964-1964.	0.6	1
120	Unrelated Cord Blood Transplantation (UCBT) In Adults In The UK: Evolution, Experience and Outcomes. A Retrospective Analysis On Behalf Of The British Society of Blood and Marrow Transplantation (BSBMT) and Eurocord. Blood, 2013, 122, 3394-3394.	0.6	1
121	Cyclophosphamide, Pomalidomide and Dexamethasone Significantly Improves Response over Poma/Dex in Relapsed/Refractory Myeloma Patients Previously Treated with Cyclophosphamide Combination Therapy - Initial Results of the Randomised Multicentre Mukseven Trial. Blood, 2018, 132, 3274-3274.	0.6	1
122	Association of genetic variants with patient reported quality of life and pain experience in patients in 0, , .	1.3	1
123	Recent Advancements in Hematology: Knowledge, Methods and Dissemination, Part 1. Hemato, 2020, 1, 10-22.	0.2	0
124	Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trial. British Journal of Haematology, 2022, 196, .	1.2	0
125	Impact of Etiological Cytogenetic Abnormalities on the Depth of Immunoparesis and Survival in Newly Diagnosed Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2021, , .	0.2	0
126	Reguatory T-Cell Subsets Demonstrate Quantitative Differences but Not Functional Abnormalities in Patients with Multiple Myeloma (MM) Compared with Healthy Controls.. Blood, 2007, 110, 3511-3511.	0.6	0

#	Article	IF	Citations
127	Reduced Intensity Allogeneic Tranplants Are Well Tolerated In Patients Over the Age of 60: Identification of Factors Predicting Overall Survival. Blood, 2010, 116, 2361-2361.	0.6	0
128	Feasibility and Efficacy of Administration of Bortezomib-Containing Regimens to Patients Over the Age of 70 Years. Blood, 2010, 116, 5035-5035.	0.6	0
129	Deletion 13, Detected by Metaphase Analysis, Is Not a Significant Prognostic Indicator In Myeloma. Blood, 2010, 116, 2980-2980.	0.6	0
130	The Role of High Dose Chemotherapy and Autologous Stem Cell Transplantation In Patients with Multiple Myeloma Refractory to Initial Induction Therapy. Blood, 2010, 116, 1341-1341.	0.6	0
131	Allogeneic Stem Cell Transplantation Induces Long Term Survival in Pateitns with Advanced Chronic Myeloid Leukaemia:A Study of the British Society for Blood and Marrow Transplantation,. Blood, 2011, 118, 4125-4125.	0.6	0
132	BEAM-Campath Allogeneic Stem Cell Transplantation for Aggressive Non-Hodgkin's Lymphomas. An Analysis of Outcomes From the BSBMT. Blood, 2012, 120, 2039-2039.	0.6	0
133	Lenalidomide Redresses the Effector T Cell:Treg Cell Imbalance in Patients with Multiple Myeloma.. Blood, 2012, 120, 2977-2977.	0.6	0
134	Optimizing induction and pretransplant consolidation for myeloma: Results of Myeloma XI, a phase III trial comparing different IMiDs.. Journal of Clinical Oncology, 2014, 32, 8537-8537.	0.8	0
135	Characterisation of Long-Term Responders to First-Line Myeloma Therapy - Results from the UK Myeloma IX and XI Trials. Blood, 2018, 132, 2000-2000.	0.6	0
136	POEMS Syndrome and Disease Produced by Other Monoclonal Immunoglobulins. , 2019, , 615-619.		0
137	Subsequent Treatments, Responses and Survival in the Real World for Patients with Relapsed Multiple Myeloma Following Treatment with Lenalidomide. Blood, 2019, 134, 4340-4340.	0.6	0